Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase III drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tiragolumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tiragolumab overview

Tiragolumab (RG-6058, MTIG-7192A, anti-TIGIT) is under development for the treatment of advanced or metastatic hepatocellular carcinoma (HCC), bladder cancer, advanced rectal cancer, advanced or metastatic solid tumors, head and neck squamous cell carcinoma (SCCHN) involving the oropharynx, oral cavity, larynx, or hypopharyngeal cancers, metastatic esophageal squamous cell carcinoma,  gastroesophageal junction carcinomas, triple negative breast cancer, B-Cell Non-Hodgkin Lymphoma, locally advanced, recurrent, or metastatic incurable tumors, adenocarcinoma of the cervix, small-cell lung cancer, brain metastases, non-squamous NSCLC, HER2 negative breast cancer and non-small cell lung cancer. The drug candidate is administered as an intravenous (IV) infusion. It acts by targeting TIGIT protein.

It was also under development for the treatment of relapsed/refractory multiple myeloma, cervical cancer, gastric cancer or adenocarcinoma of gastroesophageal junction, relapsed/refractory B-cell non-Hodgkin lymphoma

Genentech USA overview

Genentech USA (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including oncology, immunology, ophthalmology, metabolism, neurology, and infectious disease, among others. The company’s pipeline products include Emicizumab (RG6013, ACE910), a bispecific monoclonal antibody used to replace the function of protein in the blood clotting process; and Entrectinib (RXDX-101, RG6268), a CNS-active tyrosine-kinase inhibitor intended for the treatment of non-small cell lung cancer; among others. The company has partnership with BioLineRx, Charles River Laboratories International, Amunix, among others. Genentech is headquartered in South San Francisco, California, the US.

For a complete picture of Tiragolumab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.